This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Edward Bowman: Innovator in Anti-Cancer Therapies
Introduction
Edward Bowman is a notable inventor based in Bowman, California. He has made significant contributions to the field of cancer treatment through his innovative research and development of combination therapies. His work focuses on utilizing CTLA-4 and PD-1 blocking agents to enhance the effectiveness of cancer therapies.
Latest Patents
Edward Bowman holds a patent for "Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents." This patent discloses combination therapies that include an effector-silent anti-CTLA-4 antibody or fragment, along with an anti-PD-1 or anti-PD-L1 antibody or fragment. This innovative approach aims to improve the efficacy of cancer treatments by targeting multiple pathways.
Career Highlights
Bowman is currently associated with Merck Sharp & Dohme Corporation, where he continues to advance his research in oncology. His dedication to developing effective cancer therapies has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Edward Bowman has collaborated with notable professionals in his field, including Drake LaFace and Juha Punnonen. These partnerships have contributed to the advancement of his research and the development of innovative therapies.
Conclusion
Edward Bowman's work in anti-cancer combination therapies represents a significant advancement in the fight against cancer. His innovative approaches and collaborations continue to pave the way for new treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile